Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
The DOI matches its Crossref record; 234 of the 235 references it cites were found in a registry or an index.
Abstract
The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is no solid evidence from liver imaging and/or histology in regards to a beneficial effect of metformin on MASLD components in clinical studies [168,169].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [168]
In the citing paper
“Peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), FXR and THR (particularly THR-β) are the most extensively studied receptors that are targets for therapy.20–22”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [22]
In the citing paper
“Activation of PPARs, particularly PPARβ/δ stimulation, promote the anti-inflammatory polarisation of hepatic macrophages,22,68”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [22]
In the citing paper
“Furthermore, controversially documented inter-species differences in PPAR-α expression [119][120][121] complicate the translation of data from preclinical studies to patients.[122,123]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [123]
Citations
Cites
1 retracted
Hou, X., & Pei, F. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0522-y · Cited by 36
RetractedGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Inflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationResolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Self-citationMaeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
Self-citationLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Self-citationHome, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene
Fajas, L., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre, A.-M., Saladin, R., Najib, J., Laville, M., Fruchart, J.-C., Deeb, S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18779 · Cited by 1,188
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,174
The integrative biology of type 2 diabetes
Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167
Self-citationPioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,060
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Self-citationTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Self-citationTilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationInternational Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Biochemistry of mammalian peroxisomes revisited
Wanders, R. J. A., & Waterham, H. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133329 · Cited by 995
Sorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Self-citationMolecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 852
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 736
The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis.
Crewe, C., An, Y. A., & Scherer, P. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88883 · Cited by 732
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 697
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
Vidal-Puig, A., Jimenez-Liñan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S., & Moller, D. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118703 · Cited by 655
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 624
Self-citationMolecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
Francque, S. M., van der Graaff, D., & Kwanten, W. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.005 · Cited by 556
Self-citationSattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555
Xu, H. E., Lambert, M. H., Montana, V. G., Plunket, K. D., Moore, L. B., Collins, J. L., Oplinger, J. A., Kliewer, S. A., Gampe, R. T., McKee, D. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241410198 · Cited by 538
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Self-citationIdentification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver
Chakravarthy, M. V., Lodhi, I. J., Yin, L., Malapaka, R. R. V., Xu, H. E., Turk, J., & Semenkovich, C. F. (2009) · Cell · doi:10.1016/j.cell.2009.05.036 · Cited by 533
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Inflammasomes in liver diseases
Szabo, G., & Csak, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.035 · Cited by 495
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationThiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Peroxisome proliferator activated receptor-alpha expression in human liver.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448
Peroxisome Proliferator Activated Receptor-α Expression in Human Liver
Palmer, C. N. A., Hsu, M.-H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.1.14 · Cited by 416
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Self-citationPathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Self-citationThe role and regulation of the peroxisome proliferator activated receptor alpha in human liver
Kersten, S., & Stienstra, R. (2017) · Biochimie · doi:10.1016/j.biochi.2016.12.019 · Cited by 394
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants
Millett, E. R. C., Peters, S. A. E., & Woodward, M. (2018) · BMJ · doi:10.1136/bmj.k4247 · Cited by 364
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Self-citationCanaple, L., Rambaud, J., Dkhissi-Benyahya, O., Rayet, B., Tan, N. S., Michalik, L., Delaunay, F., Wahli, W., & Laudet, V. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0052 · Cited by 352
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Self-citationLemberger, T., Saladin, R., Vázquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., Wahli, W., & Auwerx, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1764 · Cited by 329
Sberna, A. L., Bouillet, B., Rouland, A., Brindisi, M. C., Nguyen, A., Mouillot, T., Duvillard, L., Denimal, D., Loffroy, R., Vergès, B., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13565 · Cited by 322
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313
Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312
Self-citationLefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310
Self-citationReid, B. N., Ables, G. P., Otlivanchik, O. A., Schoiswohl, G., Zechner, R., Blaner, W. S., Goldberg, I. J., Schwabe, R. F., Chua, S. C., & Huang, L.-S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800533200 · Cited by 307
A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
Basaranoglu, M., Acbay, O., & Sonsuz, A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80243-8 · Cited by 305
Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
Rakhshandehroo, M., Hooiveld, G., Müller, M., & Kersten, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006796 · Cited by 305
Stepanova, M., Rafiq, N., & Younossi, Z. M. (2010) · Gut · doi:10.1136/gut.2010.213553 · Cited by 303
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramirez, G., & DeFronzo, R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
Bril, F., Barb, D., Portillo‐Sanchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. (2017) · Hepatology · doi:10.1002/hep.28985 · Cited by 288
Self-citationContribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease
Tamura, S., & Shimomura, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524930 · Cited by 287
Apostolopoulou, M., Gordillo, R., Koliaki, C., Gancheva, S., Jelenik, T., De Filippo, E., Herder, C., Markgraf, D., Jankowiak, F., Esposito, I., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1318 · Cited by 284
Self-citationRoles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism
Lefere, S., & Tacke, F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.004 · Cited by 278
Self-citationPPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Dai, W., Ye, L., Liu, A., Wen, S. W., Deng, J., Wu, X., & Lai, Z. (2017) · Medicine · doi:10.1097/md.0000000000008179 · Cited by 268
Kupffer cell activation is a causal factor for hepatic insulin resistance
Lanthier, N., Molendi-Coste, O., Horsmans, Y., van Rooijen, N., Cani, P. D., & Leclercq, I. A. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00391.2009 · Cited by 257
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0019 · Cited by 256
Ortiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V. G., Hardies, J., & Cusi, K. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 253
Self-citationPPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
Diabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.014 · Cited by 236
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes
Cholankeril, G., Wong, R. J., Hu, M., Perumpail, R. B., Yoo, E. R., Puri, P., Younossi, Z. M., Harrison, S. A., & Ahmed, A. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4684-x · Cited by 234
van der Meer, R. W., Rijzewijk, L. J., de Jong, H. W. A. M., Lamb, H. J., Lubberink, M., Romijn, J. A., Bax, J. J., de Roos, A., Kamp, O., Paulus, W. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.803916 · Cited by 233
A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use
Liu, S., Brown, J. D., Stanya, K. J., Homan, E., Leidl, M., Inouye, K., Bhargava, P., Gangl, M. R., Dai, L., Hatano, B., et al. (2013) · Nature · doi:10.1038/nature12710 · Cited by 231
Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes
Guan, D., Xiong, Y., Borck, P. C., Jang, C., Doulias, P.-T., Papazyan, R., Fang, B., Jiang, C., Zhang, Y., Briggs, E. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.031 · Cited by 226
Glitazones: clinical effects and molecular mechanisms
Stümvoll, M., & Häring, H. (2002) · Annals of Medicine · doi:10.1080/713782132 · Cited by 225
Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease
Newton, K. P., Hou, J., Crimmins, N. A., Lavine, J. E., Barlow, S. E., Xanthakos, S. A., Africa, J., Behling, C., Donithan, M., Clark, J. M., et al. (2016) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2016.1971 · Cited by 224
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Krenkel, O., Hundertmark, J., Abdallah, A. T., Kohlhepp, M., Puengel, T., Roth, T., Branco, D. P. P., Mossanen, J. C., Luedde, T., Trautwein, C., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318382 · Cited by 220
Self-citationCariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
Cheung, C., Akiyama, T. E., Ward, J. M., Nicol, C. J., Feigenbaum, L., Vinson, C., & Gonzalez, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0322 · Cited by 215
Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209
Self-citationJain, M. R., Giri, S. R., Bhoi, B., Trivedi, C., Rath, A., Rathod, R., Ranvir, R., Kadam, S., Patel, H., Swain, P., et al. (2018) · Liver International · doi:10.1111/liv.13634 · Cited by 206
Distinct Circadian Signatures in Liver and Gut Clocks Revealed by Ketogenic Diet
Tognini, P., Murakami, M., Liu, Y., Eckel-Mahan, K. L., Newman, J. C., Verdin, E., Baldi, P., & Sassone-Corsi, P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.015 · Cited by 202
Holden, P., & Tugwood, J. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0220001 · Cited by 201
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Interorgan Metabolic Crosstalk in Human Insulin Resistance
Gancheva, S., Jelenik, T., Álvarez-Hernández, E., & Roden, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00015.2017 · Cited by 192
Self-citationLawrence, J. W., Li, Y., Chen, S., DeLuca, J. G., Berger, J. P., Umbenhauer, D. R., Moller, D. E., & Zhou, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103306200 · Cited by 190
Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex
Ma, X., Wang, D., Zhao, W., & Xu, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00473 · Cited by 187
Hoekstra, M., Kruijt, J. K., Van Eck, M., & van Berkel, T. J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301189200 · Cited by 183
PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part I: PPAR-α
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2016-0059 · Cited by 183
Liu, Y., Colby, J. K., Zuo, X., Jaoude, J., Wei, D., & Shureiqi, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113339 · Cited by 182
Byrne, C. D., & Targher, G. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303034 · Cited by 179
Self-citationDerosa, G., Sahebkar, A., & Maffioli, P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25804 · Cited by 165
Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis
Zhou, Z., Xu, M.-J., Cai, Y., Wang, W., Jiang, J. X., Varga, Z. V., Feng, D., Pacher, P., Kunos, G., Torok, N. J., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.01.003 · Cited by 164
Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells
Fan, Y., Wang, Y., Tang, Z., Zhang, H., Qin, X., Zhu, Y., Guan, Y., Wang, X., Staels, B., Chien, S., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.149815 · Cited by 163
Belfort, R., Berria, R., Cornell, J., & Cusi, K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1487 · Cited by 159
Self-citationNon-alcoholic fatty liver disease and risk of type 2 diabetes
Lallukka, S., & Yki‐Järvinen, H. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.006 · Cited by 159
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation
Liu, S., Hatano, B., Zhao, M., Yen, C.-C., Kang, K., Reilly, S. M., Gangl, M. R., Gorgun, C., Balschi, J. A., Ntambi, J. M., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.138115 · Cited by 153
Bays, H. E., Schwartz, S., Littlejohn, T., Kerzner, B., Krauss, R. M., Karpf, D. B., Choi, Y.-J., Wang, X., Naim, S., & Roberts, B. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1061 · Cited by 152
Nonalcoholic Fatty Liver Disease in Children
Mann, J., Valenti, L., Scorletti, E., Byrne, C., & Nobili, V. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1627456 · Cited by 152
Self-citationAuboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diabetes.46.8.1319 · Cited by 151
Girroir, E. E., Hollingshead, H. E., He, P., Zhu, B., Perdew, G. H., & Peters, J. M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.086 · Cited by 150
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
Lomonaco, R., Bril, F., Portillo-Sanchez, P., Ortiz-Lopez, C., Orsak, B., Biernacki, D., Lo, M., Suman, A., Weber, M. H., & Cusi, K. (2016) · Diabetes Care · doi:10.2337/dc15-1876 · Cited by 146
Self-citationSanderson, L. M., Boekschoten, M. V., Desvergne, B., Müller, M., & Kersten, S. (2010) · Physiological Genomics · doi:10.1152/physiolgenomics.00127.2009 · Cited by 145
Ganz, M., Bukong, T. N., Csak, T., Saha, B., Park, J.-K., Ambade, A., Kodys, K., & Szabo, G. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0552-7 · Cited by 144
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome
Wainwright, P., & Byrne, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030367 · Cited by 143
Self-citationPawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., & Staels, B. (2014) · Hepatology · doi:10.1002/hep.27297 · Cited by 141
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications
Angulo, P., Machado, M., & Diehl, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550065 · Cited by 136
Kaul, U., Parmar, D., Manjunath, K., Shah, M., Parmar, K., Patil, K. P., & Jaiswal, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0884-3 · Cited by 134
Wettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 132
Self-citationHonda, Y., Kessoku, T., Ogawa, Y., Tomeno, W., Imajo, K., Fujita, K., Yoneda, M., Takizawa, T., Saito, S., Nagashima, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42477 · Cited by 131
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., Anstee, Q. M., & Workshop, O. B. O. T. P. O. T. A. (2019) · Hepatology · doi:10.1002/hep.30782 · Cited by 120
Self-citationJacome-Sosa, M. M., & Parks, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000080 · Cited by 118
Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92264 · Cited by 117
Self-citationJani, R. H., Pai, V., Jha, P., Jariwala, G., Mukhopadhyay, S., Bhansali, A., & Joshi, S. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0253 · Cited by 116
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Self-citationPioglitazone in the treatment of NASH: the role of adiponectin
Gastaldelli, A., Harrison, S., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 113
Self-citationZizzo, G., & Cohen, P. L. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0081-4 · Cited by 110
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01285 · Cited by 110
Spence, J. D., Viscoli, C. M., Inzucchi, S. E., Dearborn-Tomazos, J., Ford, G. A., Gorman, M., Furie, K. L., Lovejoy, A. M., Young, L. H., Kernan, W. N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0079 · Cited by 109
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Ruzehaji, N., Frantz, C., Ponsoye, M., Avouac, J., Pezet, S., Guilbert, T., Luccarini, J.-M., Broqua, P., Junien, J.-L., & Allanore, Y. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208029 · Cited by 101
Haczeyni, F., Wang, H., Barn, V., Mridha, A. R., Yeh, M. M., Haigh, W. G., Ioannou, G. N., Choi, Y., McWherter, C. A., Teoh, N. C. ‐., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1072 · Cited by 101
Role of MicroRNAs in NAFLD/NASH
Szabó, G., & Csák, T. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4002-4 · Cited by 99
Balas, B., Belfort, R., Harrison, S. A., Darland, C., Finch, J., Schenker, S., Gastaldelli, A., & Cusi, K. J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.013 · Cited by 93
Self-citationHepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 90
Larter, C. Z., Yeh, M. M., Van Rooyen, D. M., Brooling, J., Ghatora, K., & Farrell, G. C. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06939.x · Cited by 89
PPARbeta/delta ligands as modulators of the inflammatory response.
Kilgore, K. S., & Billin, A. N. (2008) · PubMed · Cited by 87
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E., Uzunova, K., Kalinov, K., & Vekov, T. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 87
McVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 85
Gut microbiota, fatty liver disease, and hepatocellular carcinoma
Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 84
Self-citationJayakumar, S., & Loomba, R. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15314 · Cited by 84
Chen, L., Li, L., Chen, J., Li, L., Zheng, Z., Ren, J., & Qiu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6466 · Cited by 83
Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARα
Roberts, R. A., James, N. H., Hasmall, S. C., Holden, P. R., Lambe, K. G., Macdonald, N., West, D., Woodyatt, N. J., & Whitcome, D. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00243-x · Cited by 80
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Choi, Y., Roberts, B. K., Wang, X., Geaney, J. C., Naim, S., Wojnoonski, K., Karpf, D. B., & Krauss, R. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.029 · Cited by 80
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
Avouac, J., Konstantinova, I., Guignabert, C., Pezet, S., Sadoine, J., Guilbert, T., Cauvet, A., Tu, L., Luccarini, J., Junien, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210821 · Cited by 80
Gachon, F., Leuenberger, N., Claudel, T., Gos, P., Jouffe, C., Fleury Olela, F., de Mollerat du Jeu, X., Wahli, W., & Schibler, U. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002862108 · Cited by 79
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
Inzucchi, S. E., Viscoli, C. M., Young, L. H., Furie, K. L., Gorman, M., Lovejoy, A. M., Dagogo-Jack, S., Ismail-Beigi, F., Korytkowski, M. T., Pratley, R. E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0798 · Cited by 75
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Wilding, J. P. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01601.x · Cited by 73
Tada, T., Toyoda, H., Sone, Y., Yasuda, S., Miyake, N., Kumada, T., & Tanaka, J. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14734 · Cited by 73
BELL, A. R., SAVORY, R., HORLEY, N. J., CHOUDHURY, A. I., DICKINS, M., GRAY, T. J. B., SALTER, A. M., & BELL, D. R. (1998) · Biochemical Journal · doi:10.1042/bj3320689 · Cited by 67
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67
Kalavalapalli, S., Bril, F., Koelmel, J. P., Abdo, K., Guingab, J., Andrews, P., Li, W.-Y., Jose, D., Yost, R. A., Frye, R. F., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00023.2018 · Cited by 66
Self-citation
Research works printed but not linked: 3
- CymaBay Therapeutics. CymaBay Therapeutics reports topline 12-week data from an ongoing phase 2b study of seladelpar in patients with nonalcoholic steatohepatitis. CymaBay https://ir.cymabay.com/press-releases?year=2019&page=2 (2019).
- CymaBay Therapeutics. CymaBay Therapeutics halts clinical development of seladelpar. CymaBay https://ir.cymabay.com/press-releases?year=2019&page=1 (2019).
- Bril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 42, 1481–1488 (2019). · DOI · Paper page
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationA Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationA Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Self-citationPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citation
Metadata
- Authors
- Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F.
- Affiliations
- University of Antwerp (BE)
- Duke University (US)
- University Hospital Southampton NHS Foundation Trust (GB)
- University of Florida Health (US)
- University Hospital of Bern (CH)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Brigham and Women's Hospital (US)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Francque, Sven
- ORCID
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2020-10-22
- Volume
- 18
- Issue
- 1
- Pages
- 24-39
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3094033262
- Cited by
- 316
- References
- 235
- Citations by year
- 2026: 38 · 2025: 41 · 2024: 62 · 2023: 62 · 2022: 70 · 2021: 41 · 2020: 2
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- nonalcoholic steatohepatitis, peroxisome proliferator-activated receptors, non-alcoholic fatty liver disease, metabolic syndrome, obesity, type 2 diabetes, liver fibrosis, PPAR agonists, gut microbiota
- MeSH terms
- Humans, Inflammation, Obesity, Disease Progression, Metabolic Syndrome, Peroxisome Proliferator-Activated Receptors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.